Background 

MacroGenics has a diverse product development portfolio:

• Humanized anti-CD3 monoclonal antibody (Mab), teplizumab, for autoimmune disorders
• Humanized anti-CD16 (FcyRIII) and soluble Fc receptors (FcR) for autoimmune diseases
• Humanized anti-CD32B (FcyRIIB) for oncology, autoimmunity, allergy, and cancer adjuvants 
• Humanized anti-West Nile virus Mab
• Antibody cocktail for postexposure treatment of Smallpox

MacroGenics' key assets in building a sustainable pipeline are:

• A diverse development portfolio of novel therapeutic monoclonal antibodies and fusion proteins to treat cancer, autoimmune disorders, allergies, and infectious diseases.
• GMP manufacturing for producing clinical trial material.
• An integrated platform for target discovery to identify and characterize novel cancer antigens.
• A broad, enabling Fc engineering technology for enhancing monoclonal antibodies.
• An intellectual property portfolio containing both know-how and patents with claims that cover: (a) the compositions and use of drug targets for autoimmune disorders, cancer, and infectious diseases, (b) Fc engineering, (c) transgenic animal models, and (d) genetic immunization.
• A proactive in-licensing approach focused on building a rich and diversified product development pipeline.
• A seasoned management team with decades of collective experience in therapeutic antibody and vaccine discovery, clinical development, regulatory affairs and corporate partnering.